



D. BORAL
— CAPITAL —

August 2025



\$4,000,000

Uplisting

Co-Bookrunner



*For more information please
contact:*

Investment Banking

Gaurav Verma
Co-Head of Investment Banking
Direct: +1 (929) 528-0912
gverma@dboralcapital.com

John Park
Vice President
Direct: +1 (929) 528-0864
jpark@dboralcapital.com

Bella Tarbet
Analyst
Direct: +1 (929) 528-0982
btarbet@dboralcapital.com

Michael Fellman
Analyst
Direct: +1 (929) 528-0986
mfellman@dboralcapital.com

Equity Capital Markets

Philip Wiederlight
Chief Operating Officer
Direct: +1 (929) 625-1539
pwiederlight@dboralcapital.com

Mark Iorio
Director
Direct: +1 (929) 528-0913
miorio@dboralcapital.com

D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq: PPCB) in Connection with its \$4,000,000 Uplisting

Transaction Information

On August 19, 2025, Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that it closed an underwritten public offering of 1,000,000 shares of its common stock, par value \$0.001 per share, at a price of \$4.00 per share. The shares of common stock commenced trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol, “PPCB”. The Company received aggregate gross proceeds of \$4,000,000 from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has also granted the underwriter a 45-day option to purchase up to 150,000 additional shares of common stock at the public offering price, less underwriting discounts.

D. Boral Capital LLC acted as lead bookrunner for the Offering.

About Propanc Biopharma, Inc.

Propanc is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.

The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.

A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately \$35 billion in capital since its inception in 2020, executing ~350 transactions across a broad range of investment banking products.

D. Boral Capital is a member of FINRA and SIPC.



D. BORAL
— CAPITAL —